Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec/insulin aspart versus insulin glargine plus insulin aspart in type 2 diabetes requiring treatment intensification
2015-004768-12Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of insulin degludec, insulin aspart and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycosylated haemoglobin (HbA1c). Started May 2016; status: completed.
02
Drugs
insulin degludecinsulin aspartinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-004768-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004768-12.